Deepbridge Life Sciences EIS

Deepbridge Life Sciences EIS

PROVIDED BY
STRUCTUREFund
MIN. INVESTMENT£10,000
SECTORHealthcare and Services
CLOSING DATEEvergreen
Risk score
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

Synthetic Risk and Reward Indicator (SRRI) is calculated by the fund manager following guidelines set out by the European Securities and Markets Authority (ESMA)

Important Information In relation to regulated business for retail clients, Deepbridge Advisers Limited (FRN:609786) is an Appointed Representative of Enterprise Investment Partners LLP "EIP" (FRN: 604439) which is authorised and regulated by the Financial Conduct Authority. This is a financial promotion approved by Enterprise Investment Partners LLP "EIP" (FRN: 604439) for the purposes of section 21 Financial Services and Markets Act 2000.
Deepbridge

Investments shown on this site put your capital at risk and should be considered by experienced investors only. Learn more

Summary

The Deepbridge Life Sciences EIS represents an opportunity for private investors to participate in a selected portfolio of healthcare innovation, whilst taking advantage of the tax benefits available under the Enterprise Investment Scheme. The Deepbridge Life Sciences EIS focuses principally, but not exclusively, on three sectors:

• Biopharmaceuticals

• Biotechnology

• Medical Technology.

The Deepbridge Life Sciences EIS is not an unregulated collective investment scheme.


Application Process Update

In light of events happening around the world, managers have been revising their application acceptance procedures in close co-ordination with Custodians to ensure applications and funds are processed efficiently. Once you have submitted your application to CoInvestor a member of staff will contact you directly with further instructions for the relevant fund manager.

Highlights

  • Usually monthly deployments
  • The global life sciences industry is one of the leading sources of innovation available today
  • No management fees levied on the investor, at the point of investment for subscriptions, which ensures up to 100% tax efficiency.
  • Diversified portfolio of up to ten investee companies focused on: Biopharmaceuticals, Biotechnology, Medical Technology
  • Experienced and aligned management team who take a hands-on approach.

Investment strategy

The Deepbridge Life Sciences EIS will only be invested in Investee Companies which propose to follow a conservative business model that is in line with the investment strategy of the Deepbridge EIS. In doing so, Deepbridge intends to appoint one or more of officers from Deepbridge to the board of each of the Investee Companies, once the decision to invest in each such company has been made.

Any decisions or actions required in relation to the investor’s rights and interests in the Investee Companies will be taken by the Manager, acting in its sole discretion. Deepbridge will provide monitoring services to each Investee Company, including appointing a director to the board to assist the Investee Company in delivering and monitoring adherence to, and compliance with, its business plan.

Exit strategy

Investee Companies will need to demonstrate a clear exit strategy in order to provide investors with their returns. Deepbridge considers that flexibility is key, therefore the Deepbridge team will assess any opportunity to capitalise on exit opportunities, notwithstanding the three year EIS period, if an early exit is in the Investors’ best interests. 

In any event, by the end of the initial three year period, if not before, the Investee Companies should have established revenue streams supported by a three year track record. As such, Deepbridge believes that either a sale of the Investee Companies, or a sale or refinancing of the assets owned by the Investee Companies, will enable funds to be returned to Investors.


Risks

Investments in unquoted companies carries high risks and investors could lose all funds invested. Investors should not invest if capital is required in the near term. No established market exists for the trading of shares in private companies, making it difficult to sell shares. The value of tax reliefs depend on personal circumstances and may be subject to change in the future. The availability of tax reliefs depends on the Company invested in maintaining its qualifying status. Past performance is not a guide to the future performance of an investment, and investors are encouraged to take independent legal, tax and financial advice before considering an investment.

Market approach

The Deepbridge Life Sciences EIS will target companies that are post-proof of concept and in the early stages of their  commercialisation, which possess a particular innovationor product development that has a significant high growth opportunity either in new or established healthcare markets. These companies can typically accelerate rapidly, generating better than average results within a medium-term time frame.

The aim of portfolio diversification is to maximise the likelihood of overall returns to investors by aiming to mitigate technologyspecific investment risk. Furthermore, the time-horizon of each Investee Company is expected to differ, with some expected to realise investor returns sooner than others.

The scarcity of available capital for small and mediumsized enterprises, together with the Supervisory Investment Committee members’ expertise in the relevant sectors, is expected to enable both the Investment Adviser and the Manager to negotiate highly attractive entry terms with Investee Companies thus creating greater upside potential for investors.

Innovation management partners, such as We Are Nova Ltd, may take a significant minority equity position in those companies, in exchange for their services provided to such companies. We Are Nova Ltd describes itself as a digital development organisation that specialises in creating and growing digital start-up businesses. Working with digital innovations, Nova confirms that it operates a partnershipstyle approach to helping entrepreneurs from an initial idea to discovering its market and building the product.

Key team

Dr. Savvas Neophytou - Partner & Head of Life Sciences

Savvas is the Head of Life Sciences at Deepbridge. Prior to joining Deepbridge, Savvas enjoyed a 15 year career in the City, working as an investment banker at JP Morgan, Bear Stearns, Shore Capital, Cantor Fitzgerald, and Panmure Gordon. Savvas was also CEO of telemedicine business Now Healthcare Group.  As a highly acclaimed analyst, Savvas has won multiple awards, most recently in 2015 when Savvas was ranked 2nd overall in the prestigious Reuters Starmine survey, a position he also held in 2014. In the same year, Savvas was also runner-up in the CityAM Analyst of the Year awards. Savvas holds a PhD in psychopharmacology from Nottingham University and a BSc (Hons) degree in pharmacology from Manchester University.

Ben Carter - Investment Manager, Life Sciences

Ben is Investment Manager within the Life Sciences team at Deepbridge. Prior to this role, Ben had been the managing director of Touchpoint Service and commercial director of Telmenow the healthcare equipment focussed e-commerce platform. Ben has also been chief commercial officer at Now Healthcare Group, a leading telemedicine provider with its Dr Now app.

With a BA (Hons) in Management from the University of Manchester, Ben’s other corporate experience includes being commercial director at Possum, market leaders in the provision, installation and support of many types of electronic assistive technology

Alison Maughan - Investment Manager, Life Sciences

Alison joined Deepbridge in February 2019 as Investment Manager, Life Sciences.  Alison works with prospective and existing life sciences investee companies as part of the Deepbridge EIS and SEIS propositions.

In addition to graduating from the University of Oxford with a BA in Biological Sciences, Alison brings corporate VC experience to the Deepbridge team.

Documents

  • Lorem ipsum dolor
  • Nullam rutrum mauris
  • Mauris rhoncus facilisis

Due to regulatory requirements, only registered investors can access these documents.

Receive access by registering for an account.

Fee summary

The Deepbridge Life Sciences EIS is a manager fee-free EIS opportunity at the point of investment for subscriptions received by a financial adviser. Investors are therefore not charged any manager fees at the point of investment, if subscriptions are received via a financial adviser. Upfront and ongoing manager fees are paid by the Investee Companies: this advantage allows investors to enjoy up to 100% of EIS tax benefits and to have up to 100% of their investment actually put to work earning investment returns. Please note that, in line with the Retail Distribution Review, Deepbridge can facilitate financial adviser fees: this may result in a deduction from your subscription prior to the deployment of funds.

Performance incentive fee: an incentive fee of 20% of cash returned, in excess of 120% of the funds invested. Please refer to cost and fees section in the Information Memorandum for full details.